Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FibroGen
Biotech
FibroGen pays SEC $1.2M over claims of 'reverse engineered' data
FibroGen has agreed to pay $1.25 million to the SEC to settle allegations that its former chief medical officer manipulated data for the anemia drug.
James Waldron
Sep 11, 2025 10:41am
Cue Biopharma queues up J&J vet as CBO—Chutes & Ladders
Sep 13, 2024 8:30am
FibroGen lays off 75% of US staff as asset flunks 2 more trials
Jul 31, 2024 7:22am
Prostate cancer ADC breaks FibroGen's clinical losing streak
Apr 3, 2024 10:55am
Another Biogen exec hitches ride to Voyager —Chutes & Ladders
Mar 15, 2024 9:30am
FibroGen fails in DMD, continuing rotten run of phase 3 flops
Aug 30, 2023 5:54am
